Physician profile
Robert C Martinez
NPI 1477754133
$2,453.94
in general payments reported to CMS, 2019-2025
33 companies · $432 in 2025
The $432 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $161 · 2021: $474 · 2022: $367 · 2023: $319 · 2024: $377 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.53 | 2021-2025 | |
| Ucb, INC. | $187.52 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $165.27 | 2023-2024 | Rexulti |
| Lundbeck LLC | $158.22 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $155.47 | 2019-2023 | Ajovy |
| Neurocrine Biosciences, INC. | $139.55 | 2020-2025 | Ingrezza |
| Amneal Pharmaceuticals LLC | $102.53 | 2021-2023 | Rytary |
| Lilly USA, LLC | $100.09 | 2022-2025 | Amyvid, Kisunla |
| Biohaven Pharmaceuticals, INC. | $92.43 | 2021 | |
| Sumitomo Pharma America, INC. | $92.40 | 2023-2024 | Aptiom |
| Catalyst Orthoscience | $89.28 | 2025 | |
| Tanabe Pharma America, INC. | $87.42 | 2024-2025 | Radicava |
| Pfizer INC. | $86.31 | 2025 | |
| Upsher-Smith Laboratories LLC | $68.77 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $65.95 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $59.01 | 2022 | |
| Amgen INC. | $56.75 | 2021 | |
| Csl Behring | $52.94 | 2022-2023 | Hizentra |
| Axsome Therapeutics, INC. | $50.22 | 2025 | Symbravo |
| Livanova USA, INC. | $47.16 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Avion Pharmaceuticals | $46.30 | 2022 | |
| Tersera Therapeutics LLC | $41.68 | 2019 | |
| Biogen, INC. | $40.74 | 2019-2021 | |
| Neurelis, INC. | $34.40 | 2020-2021 | |
| Harmony Biosciences LLC | $26.13 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $25.96 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.56 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.16 | 2019 | |
| Ge Healthcare | $20.70 | 2025 | |
| Eisai INC. | $19.79 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.78 | 2023 | Quviviq |
| Zyla Life Sciences, INC. | $17.97 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $17.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.